PETVIVO HOLDINGS INC - PETV STOCK NEWS

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW), a biomedical device company focused on pet therapeutics, will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 10:30 AM EDT. CEO John Lai will discuss the Company’s business and innovative medical devices for companion animals. The conference runs from May 23-26, 2022, at the Fontainebleau Miami Beach Hotel, with both in-person and virtual attendance options. PetVivo has a diverse product pipeline, including the SPRYNG^™ product for joint health in pets, supported by a strong patent portfolio.

PetVivo Holdings (NASDAQ:PETV, PETVW) will present at the Planet MicroCap Showcase 2022 on May 4, 2022, at 1 PM PDT in Las Vegas. CEO John Lai will discuss the company's innovative veterinary product, Spryng with OsteoCushion Technology, designed to manage joint issues in pets. The company offers a range of treatments for companion animals and holds numerous patents. Attendees can access the live presentation via a provided webcast link. For further engagement, 1on1 investor meetings are available during the conference.

PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has appointed Rachael Schumaker as the new Business Development Manager for the Midwest Region. With over 20 years in veterinary product management and marketing, Schumaker's experience aims to enhance the introduction of the company's product, Spryng with OsteoCushion technology, to veterinarians. CEO John Lai noted this addition is crucial for achieving both short and long-term goals. PetVivo focuses on innovative medical devices for companion animals and has a product pipeline of 17 offerings, with Spryng already available for veterinarians.

PetVivo Holdings, Inc. (NASDAQ: PETV) announced the appointment of David J. Gregory as the new Regional Sales Manager for the Midwest U.S. His extensive experience in veterinary product management and distribution is expected to enhance the sales of PetVivo's product Spryng, which utilizes OsteoCushion technology for treating joint-related conditions in animals. CEO John Lai expressed confidence in Gregory's ability to drive sales, contributing to the company's goals surrounding this innovative veterinary medical device.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) has appointed Cliff Smith as the new Regional Sales Manager for the Southeast United States. With over 25 years of experience in veterinary product distribution, Smith aims to drive sales of PetVivo's innovative veterinary medical device, Spryng, which employs OsteoCushion technology. CEO John Lai stated that Smith's expertise will be vital in achieving the company's sales objectives. PetVivo is focused on veterinary devices and has a portfolio of seventeen products, including Spryng, designed to enhance the well-being of companion animals.

PetVivo Holdings (NASDAQ: PETV, PETVW) has launched two new websites as of March 4, 2022, aimed at improving information access for pet owners, veterinarians, and investors. The websites feature modern designs and easy navigation, promoting PetVivo’s product, Spryng with OsteoCushion Technology, which aids in managing joint issues in pets. CEO John Lai expresses optimism about these resources aligning with the company's vision for growth. The websites will offer comprehensive product details and facilitate ordering.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) will exhibit its lead product, SPRYNG^™ with OsteoCushion^™ Technology, at the Western Veterinary Conference from March 6-9, 2022. SPRYNG is an injectable device designed to alleviate lameness and joint-related issues in pets, especially osteoarthritis. The conference is expected to attract over 15,000 participants, providing PetVivo with a key opportunity for networking and commercialization. The company aims to leverage its innovative veterinary solutions to enhance treatment options for companion animals.

PetVivo Holdings, Inc. (Nasdaq: PETV) reported financial results for the three and nine months ending December 31, 2021. Revenue for Q3 2022 was $51,004, a significant increase from $507 in Q3 2021, driven by sales of Spryng™. However, the net loss rose to $1,642,129, or ($0.17) per share, compared to a net loss of $1,037,753, or ($0.16) per share, the previous year. Total revenues for the nine months reached $60,126, up from $7,303 in 2020. Despite the revenue growth, increased costs in sales, marketing, and general administration contributed to a wider net loss.

PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW) will announce its financial results on February 10, 2022, post-market close, followed by a conference call at 4:00 p.m. CT. Investors can register and access the live webcast through the company’s Investor Relations website. PetVivo focuses on innovative biomedical devices for animals, with a pipeline of 17 products and 21 patents, including its lead product, SPRYNG™, for treating osteoarthritis in dogs and horses. Disclosure of material nonpublic information will be made through its website and official communications.